What is HC Wainwright’s Estimate for ELEV Q3 Earnings?

Elevation Oncology, Inc. (NASDAQ:ELEV) – Investment analysts at HC Wainwright issued their Q3 2026 EPS estimates for Elevation Oncology in a research report issued to clients and investors on Tuesday, June 10th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.11) for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share.

Elevation Oncology (NASDAQ:ELEV) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04).

Several other equities research analysts have also issued reports on the company. JMP Securities reaffirmed a “market perform” rating on shares of Elevation Oncology in a research note on Tuesday. Stephens reissued an “equal weight” rating and set a $1.00 price objective (down from $5.00) on shares of Elevation Oncology in a report on Monday, March 24th. Wedbush downgraded Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 20th. Piper Sandler lowered Elevation Oncology from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $10.00 to $0.70 in a research note on Friday, March 21st. Finally, Leerink Partners downgraded shares of Elevation Oncology from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $9.00 to $1.00 in a research note on Friday, March 21st. Eleven research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Elevation Oncology has an average rating of “Hold” and a consensus price target of $3.39.

Elevation Oncology Stock Up 0.2%

ELEV opened at $0.38 on Wednesday. The stock has a market cap of $22.52 million, a PE ratio of -0.46 and a beta of 1.43. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. Elevation Oncology has a 52 week low of $0.22 and a 52 week high of $3.45. The business’s fifty day simple moving average is $0.33 and its 200 day simple moving average is $0.49.

Hedge Funds Weigh In On Elevation Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BML Capital Management LLC bought a new stake in Elevation Oncology in the first quarter valued at approximately $1,526,000. Geode Capital Management LLC increased its stake in shares of Elevation Oncology by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 1,157,572 shares of the company’s stock worth $651,000 after buying an additional 47,487 shares during the period. Millennium Management LLC increased its stake in shares of Elevation Oncology by 3.9% in the fourth quarter. Millennium Management LLC now owns 815,916 shares of the company’s stock worth $459,000 after buying an additional 30,466 shares during the period. Northern Trust Corp raised its holdings in Elevation Oncology by 15.9% during the 4th quarter. Northern Trust Corp now owns 432,620 shares of the company’s stock valued at $243,000 after buying an additional 59,392 shares during the last quarter. Finally, Allostery Investments LP bought a new stake in Elevation Oncology during the 4th quarter valued at $243,000. 83.70% of the stock is currently owned by institutional investors.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.